

Figure 1 The incidence of tyrosine-methionine-aspartate-aspartate (YMDD) motif mutant and breakthrough hepatitis was noted in patients with alanine aminotransferase level of ≤ 20 (IU/L) (a) Incidence of YMDD mutants over time ($P=0.0017$). (b) Incidence of break through hepatitis over time ($P<0.0001$).

patients in group B, and 80% in 37 patients in group C ($P=0.002$), and that of BTH in the corresponding groups was 7%, 14%, and 57% ($P<0.001$) (Fig. 3a,b).

In patients treated with lamivudine for ≥ 3 years, the increased incidence of YMDD motif mutant by HBV DNA (log copies/mL) level was 65% in patients maintaining an HBV DNA level of < 2.6 , 78% in patients maintaining an HBV DNA level of 2.6–5.0, and 92% in patients maintaining an HBV DNA level of ≥ 5.1 , and that of BTH in the corresponding groups was 10%, 18%, and 77% ($P<0.001$) (Fig. 4a,b).

The incidence of YMDD motif mutant in ≥ 3 years treatment with lamivudine in patients by both ALT

(IU/L) and HBV DNA (log copies/mL) levels during the course of lamivudine treatment was also analyzed (Table 4).

In patients maintaining HBV DNA < 2.6 and ALT ≤ 20 , the incidence of YMDD motif mutant and BTH was 38% and 7%, respectively. At the same HBV DNA level of < 2.6 and ALT 21–30, the incidence of YMDD motif mutant was 48% and BTH was 8%; whereas at ALT 31–40, YMDD motif mutant was 36% and BTH was 9%.

In patients maintaining HBV DNA 2.6–5.0 and ALT ≤ 20 , the incidence of YMDD motif mutant and BTH was 60% and 4%, respectively. At the same HBV DNA




Figure 2 incidence of BTH was 4%, 30%, and 40%, respectively, in patients with HBV DNA level of < 2.6 , 2.6–5.0, and ≥ 5.1 log copies/mL ($P = 0.004$). (a) Incidence of YMDD mutants over time ($P = 0.0001$). (b) Incidence of breakthrough hepatitis over time ($P < 0.0037$).

level, 2.6–5.0 and ALT 21–30, the incidence of YMDD motif mutant was 86% and BTH was 18%; whereas at ALT 31–40, YMDD motif mutant was 92% and BTH was 42%.

In patients maintaining HBV DNA ≥ 5.1 and ALT 31–40, YMDD motif mutant was 93% and BTH was 86%.

DISCUSSION

LONG-TERM THERAPY for CHBV can lead to the development of HBV drug-resistant mutants. Early detection of the YMDD motif mutants in lamivudine-

treated patients and timely switch to other nucleoside analogues with low viral resistance is crucial to prevent viral and biochemical flares and ineffective therapeutic response. Although development of YMDD mutants results in decreased viral susceptibility to lamivudine, viral replication rate is lower in mutant strains than in wild type.⁶

Among the 359 patients who received lamivudine for > 1 year and maintained an ALT level of ≤ 40 IU/L, the rate of YMDD motif mutant was 11% (1 year), 29% (2 year), 42% (3 year), 49% (4 year) and 61% (5 year). BTH occurrences were 3% (1 year), 8% (2 year), 13% (3 year), 15% (4 year) and 19% (5 year). The rate of




Figure 3 In patients treated with lamivudine for 3 years or more, the incidence of tyrosine-methionine-aspartate-aspartate (YMDD) motif mutant by alanine aminotransferase (IU/L) level was 58% in 113 patients in group A, 60% in 84 patients in group B, and 80% in 37 patients in group C ($P=0.002$), and that of BTH in the corresponding groups was 7%, 14%, and 57% ($P<0.001$). (a) Incidence of YMDD mutants over time ($P=0.0015$). (b) Incidence of breakthrough hepatitis over time ($P<0.0001$).

YMDD motif mutant and BTH were low after 3 or more years of treatment with lamivudine. Therefore, the year of switching treatment from lamivudine to other nucleic acid analogue will be at 3 years. Accordingly, in this study, we examined patients treated with lamivudine for <3 and ≥ 3 years.

Among the patients treated with lamivudine for <3 years, the lowest incidence of YMDD motif mutant and BTH was seen in patients with ALT <20 IU/L maintaining HBV DNA level of 2.6–5.0. The other category for lowest incidence was in patients with ALT 21–30 IU/L and HBV DNA level of <2.6 log copies/mL. In this study, within 3 years of treatment with lamivu-

dine, the group of patients with the recommended HBV DNA (<2.6 log copies/mL) and ALT maintained at 21–30 IU/L may be considered eligible to be switched to entecavir therapy as per Japanese guidelines. We, however, believe it is important to consider the prognosis for patients who are switched from lamivudine to entecavir. Similarly, in patients maintaining HBV DNA level in the range of 2.6–5.0 log copies/mL and ALT <20 IU/L, switching to dual therapy with adefovir in combination with lamivudine depends on the related viral breakthrough. In a study by Li Zhou *et al.*,¹⁶ some patients with YMDD motif mutants had significantly lower HBV DNA and ALT levels compared with baseline




Figure 4 In patients treated with lamivudine for ≥ 3 years, the increased incidence of tyrosine-methionine-aspartate-aspartate (YMDD) motif mutant by hepatitis B virus (HBV) DNA (log copies/mL) level was 65% in patients maintaining an HBV DNA level of < 2.6 , 78% in patients maintaining an HBV DNA level of 2.6–5.0, and 92% in patients maintaining an HBV DNA level of ≥ 5.1 , and that of BTH in the corresponding groups was 10%, 18%, and 77% ($P < 0.001$). (a) Incidence of YMDD mutants over time ($P = 0.0001$). (b) Incidence of breakthrough hepatitis over time ($P < 0.0001$).

values, which might be due to decreased replication efficiency of the HBV mutants.

HBeAg, severe liver disease, high HBV DNA, and low ALT levels at the baseline were factors accelerating the development of BTH. This was in confirmation of previous results.^{17–19} Development of BTH, however, was not influenced by HBV genotypes. This is probably due to the response in HBeAg-positive patients, which was comparable among those with different genotypes though it differed among HBeAg-negative patients.²⁰

In a study of Japanese adult patients treated with lamivudine for > 12 months, the YMDD motif mutation was detected in 26% patients, with 23, 16, and 21 patients

correspondingly positive for YIDD, YVDD, and YIDD + YVDD mutants. The occurrence of mutations steadily increased and two, five, and 52 patients with genotypes A, B, and C, respectively developed resistance.²¹ Lamivudine retreatment could induce rapid re-emergence of YMDD motif mutants with associated viral and hepatic flares²² and should be avoided. Next, we were interested to know if any difference in sensitivity existed in detecting YMDD mutants by the two different methods used in this study, PCR-RFLP and PCR-ELMA. We studied the rate of detection of YMDD motif mutant by both methods in 20 patients who received lamivudine for more than two years. The detection rate

Table 4 Incidences of tyrosine-methionine-aspartate-aspartate (YMDD) mutant and breakthrough hepatitis (BTH) by hepatitis B virus (HBV) DNA and alanine transaminase (ALT) level in patients during lamivudine treatment for ≥ 3 years (234 patients)

HBV DNA† (Amplicor: log copies/mL)	ALT level (IU/L)†					
	≤ 20		21–30		31–40	
	YMDD	BTH	YMDD	BTH	YMDD	BTH
< 2.6	23/60 (38%)	4/60 (7%)	29/61 (48%)	5/61 (8%)	4/11 (36%)	1/11 (9%)
2.6–5.0	30/50 (60%)	2/50 (4%)	19/22 (86%)	4/22 (18%)	11/12 (92%)	5/12 (42%)
≥ 5.1	3/3 (100%)	1/3 (33%)	0/1 (0%)	0/1 (0%)	13/14 (93%)	12/14 (86%)

†The HBV DNA and ALT levels are shown based on the treatment duration of lamivudine.

between PCR-RFLP and PCR-ELMA was similar; eight patients (40%) and nine patients (45%), respectively.²³

CONCLUSION

CORRELATION OF ALT and HBV DNA levels with YMDD motif mutant and viral breakthrough can be used as an indirect method of estimating susceptibility to develop lamivudine resistance. The low incidence of YMDD motif mutant and BTH associated with an HBV DNA level of < 2.6 log copies/mL and ALT level of ≤ 30 IU/L and an HBV DNA level of 2.6–5.0 log copies/mL and ALT level of ≤ 20 IU/L during only less than 3 year-treatments can be utilized as a clinically relevant tool to monitor patients' criteria in switching to other nucleoside analogue drugs. Using these simple methods, which can be easily pursued in clinical practice, it may be feasible in the future to switch from lamivudine to other nucleoside analogue drugs with low rates of inducing resistant mutants in CHBV patients. This is important considering the risk of continuous lamivudine treatment causing YMDD motif mutant and BTH.

REFERENCES

- Dienstag JL, Schiff ER, Wright TL *et al.* Lamivudine as initial treatment for chronic hepatitis b in the United states. *N Engl J Med* 1999; 341: 1256–63.
- Lai CL, Ching CK, Tung AK *et al.* Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. *Hepatology* 1997; 25: 241–4.
- Nevens F, Main J, Honkoop P *et al.* Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. *Gastroenterology* 1997; 113: 1258–63.
- Suzuki Y, Kumada H, Ikeda K *et al.* Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. *J Hepatol* 1999; 30: 743–8.
- Li MW, Hou W, Wo JE, Liu KZ. Character of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M mutation in patients with lamivudine resistance. *J Zhejiang Univ Sci B* 2005; 6: 664–7.
- Pallier C, Castera L, Soulier A *et al.* Dynamics of hepatitis B virus resistance to lamivudine. *J Virol* 2006; 80: 643–53.
- Allen MI, Deslauriers M, Andrews CW *et al.* Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. *Hepatology* 1998; 27: 1670–7.
- Chayama K, Suzuki Y, Kobayashi M *et al.* Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. *Hepatology* 1998; 27: 1711–16.
- Honkoop P, Niesters HG, De Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. *J Hepatol* 1997; 26: 1393–5.
- Gaillard RK, Barnard J, Lopez V *et al.* Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity. *Antimicrob Agents Chemother* 2002; 46: 1005–13.
- Bottecchia M, Souto FJ, KM O *et al.* Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil. *BMC Microbiol* 2008; 8: 11–20.
- Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. *Aliment Pharmacol Ther* 2008; 28: 167–77.
- Kumada H. *Scientific Research Grant of Ministry of Health, Labour and Welfare Research of Hepatitis Overcome Urgent Strategy*. Research Report of the Standardization of Viral

- Hepatitis treatment including Liver Cirrhosis (Japanese version). 2007.
- 14 Buster EH, van Erpecum KJ, Schalm SW *et al.* Treatment of chronic hepatitis B virus infection – Dutch national guidelines. *Neth J Med* 2008; 66: 292–306.
 - 15 Tadokoro K, Kobayashi M, Yamaguchi T *et al.* Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes. *J Virol Methods* 2006; 138: 30–9.
 - 16 Liu KZ, Hou W, Zumbika E, Ni Q. Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy. *J Zhejiang Univ Sci B* 2005; 6: 1182–7.
 - 17 Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. *Hepatology* 1999; 30: 770–4.
 - 18 Kumada H. Continued lamivudine therapy in patients with chronic hepatitis B. *Intervirology* 2003; 46: 377–87.
 - 19 Liaw YF. Therapy of chronic hepatitis B: current challenges and opportunities. *J Viral Hepat* 2002; 9: 393–9.
 - 20 Kobayashi M, Akuta N, Suzuki F *et al.* Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C. *J Med Virol* 2006; 78: 60–7.
 - 21 Suzuki F, Tsubota A, Arase Y *et al.* Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. *Intervirology* 2003; 46: 182–9.
 - 22 Kwon SY, Choe WH, Lee CH, Yeon JE, Byun KS. Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompensation after lamivudine retreatment. *World J Gastroenterol* 2008; 14: 4416–19.
 - 23 Matsuda M, Suzuki F, Suzuki Y *et al.* YMDD mutant in patients with chronic hepatitis B before treatment are not selected by lamivudine. *J Med Virol* 2004; 74: 361–6.

ISSN 1386-6346

Hepatology RESEARCH



Volume 40 Issue 2 February 2010

The Official Journal of the Japan Society of Hepatology

www.blackwellpublishing.com/hep



WILEY-
BLACKWELL

Review Article

- 115 Effects of HCV proteins in current HCV transgenic models
Jiao, J, Wang and M Sallberg

Original Articles

Clinical hepatology

- 125 Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment
M Kobayashi, F Suzuki, N Akata, H Yatsui, T Hosaka, H Sezaki, M Kobayashi, Y Kawamura, Y Suzuki, Y Arase, K Ikeda, R Mieta, S Iwasaki, S Wataniki and H Kumada
- 133 Prolonged treatment with pegylated interferon α 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan
S Watanabe, N Ebimoto, K Koike, N Izumi, H Takikawa, E Hashimoto, F Moriyasu, H Kumada, M Imawari and PERFECT Study Group
- 140 Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants
T Hosaka, F Suzuki, M Kobayashi, M Hirakawa, Y Kawamura, H Yatsui, H Sezaki, N Akata, Y Suzuki, S Saitoh, Y Arase, K Ikeda, Y Niyaoya and H Kumada
- 153 Megestrol and embryonic Qads in the treatment of advanced hepatocellular carcinoma: A prospective randomized trial in the pre-sorafenib era
A Giacomini, A Sezgin, V Avinin, P Tarantini, D Paccagnella, M Mazzocco and F Farinati
- 161 Spur cells and spur cell anemia in hospitalized patients with advanced liver disease: Incidence and correlation with disease severity and survival
T Vassiladis, A Mpoumpouris, S Vaidopoulos, O Giouleme, D Giassakis, N Grammatikos, K Soufiers, A Kakafika, K Zibmalos, K Patsouras, V Papadimitriou and N Eyiandis

Basic hepatology

Human study

- 171 Impact of amino acid substitutions in the core region of HCV on multistep hepatocarcinogenesis
T Uehara, K Takeshi, T Yoshino, K Maeta, S Ueda, T Iguchi, S Hagiwara, K Sugimachi, T Kedami, T Gon, Y Soejima, A Takekuma and Y Maehara
- 179 Expansion of CD4⁺CD25⁺FoxP3⁺ regulatory T cells in hepatitis C virus-related chronic hepatitis, cirrhosis and hepatocellular carcinoma
K Yoshizawa, T Abe, M Kito, T Kitahara, R Azawa, N Masuoka and Y Azawa

Experimental study

- 188 Intrahepatic chemotherapy using thiosensitized gel-coated rich in nude mice bearing a human hepatoma
Z Chen, L Lin, Y Yang, Z Zhang, H Cai and M Gu
- 196 Susceptibility to experimental biliary atresia linked to different hepatic gene expression profiles in two mouse strains
J Leonhardt, JF Kuebler, C Turrowski, T Hachemig, R Geffers and C Petersen
- 204 Cholestasis enhances liver ischemia/reperfusion-induced coagulation activation in rats
JJ Meek, M Ilex, M Heger, GV van der Loos, DJ Gouma and TM van Gulik
- 216 Antiangiogenesis gene armed tumor-targeting adenovirus fields multiple anti-tumor activities in human HCC xenografts in nude mice
L Fang, Y Pu, X Fu, L Sun, H Luo, S Pan, J Gu, X Guo and CSu

Case Report

- 229 Highly active antiretroviral therapy improved persistent lamivudine-resistant viremia in acute hepatitis B virus genotype A infection with coinfection of human immunodeficiency virus
M Azawa, A Isubota, K Fujise, T Kato, M Sakamoto, T Ohkusa and H Hara

Original Article

Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants

Tetsuya Hosaka,¹ Fumitaka Suzuki,¹ Masahiro Kobayashi,¹ Miharu Hirakawa,¹ Yusuke Kawamura,¹ Hiromi Yastuji,¹ Hitomi Sezaki,¹ Norio Akuta,¹ Yoshiyuki Suzuki,¹ Satoshi Saitoh,¹ Yasuji Arase,¹ Kenji Ikeda,¹ Yuzo Miyakawa² and Hiromitsu Kumada¹

¹Department of Hepatology, Toranomon Hospital, and ²Miyakawa Memorial Research Foundation, Tokyo, Japan

Aim: To identify factors for the development of hepatocellular carcinoma (HCC) in the patients who receive adefovir add-on lamivudine for treatment of lamivudine-resistant hepatitis B virus (HBV) mutants.

Methods: A total of 247 patients who developed lamivudine-resistant HBV mutants, with an increase of HBV DNA ≥ 1 log copies/mL, received adefovir dipivoxil 10 mg add-on lamivudine 100 mg daily during a median of 115 weeks (range: 25–282 weeks). They were followed for the development of HCC by imaging modalities every 3–6 months.

Results: HCC developed in 18 of the 247 (7.3%) patients. Eight factors were in significant association with the development of HCC by the univariate analysis. They included age, cirrhosis, platelet counts, levels of bilirubin, aspartate aminotransferase (AST), alanine aminotransferase and α -fetoprotein, as well as YMDD mutants at the start of

adefovir dipivoxil. By the multivariate analysis, AST levels, YIDD mutants, cirrhosis and age were independent factors for the development of HCC. By the Kaplan-Meier analysis, AST levels ≥ 70 IU/L, YIDD mutants, cirrhosis and age ≥ 50 years increased the risk of HCC ($P = 0.018$, $P = 0.035$, $P = 0.002$ and $P = 0.014$, respectively). HCC developed more frequently in the patients with than without cirrhosis at the start of adefovir (10/59 [16.9%] vs. 8/188 [4.3%], $P = 0.002$).

Conclusion: HCC can develop in cirrhotic patients receiving adefovir add-on lamivudine. Hence, the patients with baseline AST ≥ 70 IU/L and YIDD mutants would need to be monitored closely for HCC.

Key words: adefovir dipivoxil, chronic hepatitis B, hepatitis B virus, hepatocellular carcinoma, lamivudine, rescue therapy

INTRODUCTION

WORLDWIDE, AN ESTIMATED 400 million people are infected with hepatitis B virus (HBV) persistently, and one million die of decompensated cirrhosis and/or hepatocellular carcinoma (HCC) annually.^{1,2} Interferon (IFN) was introduced for treatment of chronic hepatitis B, and it has been replaced for pegylated-IFN.³ Due to substantial side-effects and requirement for injection, however, IFN-based therapies are not favored.

In 1998, lamivudine was approved as the first nucleotide(s)ide analogue for treatment of chronic hepatitis B,⁴ and then adefovir in 2002. Due to its lower costs and

safety records, lamivudine has gained a wide popularity for treatment of chronic hepatitis B. However, drug-resistant mutants arise in parallel with the duration of lamivudine, in 12.5% after 1 year, in 43.8% after 3 years, and 62.5–70.2% after 5 years.^{5,7} For preventing breakthrough hepatitis induced by lamivudine-resistant HBV mutants, additional adefovir dipivoxil 10 mg daily has been recommended;^{8,9} it is more effective than switching to adefovir monotherapy and has fewer chances of developing drug-resistant mutants.^{10,11}

Since 1995, 930 patients with chronic hepatitis have been treated with lamivudine in the Department of Hepatology at the Toranomon Hospital in Metropolitan Tokyo.¹ HBV mutants with mutations in the tyrosine-methionine-aspartic acid-aspartic acid (YMDD) motif elicited in the 247 (26.5%) patients, and they started to receive additional adefovir since December, 2002.^{12,13} However, HCC developed in 18 (7.3%) of them during the combination therapy for 25–282 weeks; HCC has

Correspondence: Dr Tetsuya Hosaka, Department of Hepatology, Toranomon Hospital, 1-3-1, Kajigaya, Takatsu-ku, Kawasaki 213-8587 Japan. Email: hosaka-p@toranomon.gr.jp
Received 25 April 2009; revision 6 June 2009; accepted 9 June 2009.

not been reported in any of the patients who have received adefovir add-on lamivudine for 5 years.^{15–17} Hence, factors for the development of HCC in the patients receiving adefovir add-on lamivudine were sought for in a retrospective study.

METHODS

Patients

OVER A PERIOD of 13 years, from September 1995 to September 2007, 930 patients with chronic hepatitis B received long-term lamivudine treatment at the Department of Hepatology at the Toranomon Hospital in Metropolitan Tokyo. Drug-resistant YMDD mutants developed in 247 (26.5%) of them, accompanied by an increase in HBV DNA ≥ 1 log copies/mL, and they received adefovir 10 mg in addition to lamivudine 100 mg daily during the median of 115 weeks (range: 25–282 weeks). They have been followed for liver function and virological markers of HBV infection monthly, as well as blood counts and tumor makers including alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II). Cirrhosis was diagnosed by laparoscopy or liver biopsy, and in the patients who had not received them, by clinical data, imaging modalities and portal hypertension. HCC was diagnosed by hypervascularity on angiography and/or histological examination, characteristic features of computed tomography, magnetic resonance imaging and ultrasonography. An informed consent was obtained from each patient in this study, and the protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a *priori* approval by the institution's human research committee.

Markers of HBV infection

Hepatitis B e antigen (HBeAg) was determined by enzyme-linked immunosorbent assay (ELISA) with commercial kits (HBeAg EIA, Institute of Immunology, Tokyo). HBV DNA was quantitated by the Amplicor monitor assay (Roche Diagnostics, Tokyo) with a dynamic range over 2.6–7.6 log copies/mL. Genotypes of HBV were determined serologically by the combination of epitopes expressed on the pre-S2 region product, which is specific for each of the seven major genotypes (A–G),^{18,19} with use of commercial kits (HBV Genotype EIA, Institute of Immunology).

Detection of YMDD mutants

YMDD mutants were determined by polymerase chain reaction (PCR)-based enzyme-linked mini-sequence

assay (PCR-ELIMA) with commercial kits (Genome Science Laboratories, Tokyo).

Statistical analyses

Categorical variables were compared between groups by the χ^2 test, and non-categorical variables by the Mann-Whitney *U*-test. A *P*-value < 0.05 was considered significant. Factors associated with HCC by univariate analysis were evaluated by the multivariate analysis by the stepwise Cox proportional hazard model. Development of HCC with time was analyzed by the Kaplan-Meier method, and differences were evaluated by the log-rank test. Data were analyzed by the SPSS software, version 11.0 (Chicago, IL).

RESULTS

Baseline characteristics of the patients who did and who did not develop hepatocellular carcinoma during adefovir add-on lamivudine treatment

TABLE 1 COMPARES characteristics at the start of adefovir between the 18 patients who developed HCC and the 229 who did not. Eight factors were associated with the development of HCC by the univariate analysis. They included age, cirrhosis, platelet counts, bilirubin, AST, alanine aminotransferase (ALT) and α -fetoprotein (AFP) levels, as well as YMDD mutants. HCC developed more frequently in the patients with than without cirrhosis at the start of adefovir (10/59 [16.9%] vs. 8/188 [4.3%], *P* = 0.002). There were 61 (26.6%) patients who had cirrhosis at the start of adefovir. Of them, one of the 18 (2.2%) with HCC and 18 of the 229 (2.2%) without HCC presented with decompensation; no patients developed decompensation after the start of adefovir.

Rates of HBV DNA disappearance from serum (< 2.6 log copies/mL) were: 55% (113/207) at 1 year, 71% (119/168) at 2 years, 77% (78/101) at 3 years and 85% (35/41) at 4 years. Rates of AST normalization (< 38 IU/L) were: 87% (179/207) at 1 year, 90% (151/168) at 2 years, 92% (93/101) at 3 years and 95% (39/41) at 4 years; and those of ALT normalization (< 50 IU/L) were: 88% (183/207) at 1 year, 91% (153/168) at 2 years, 93% (94/101) at 3 years and 98% (40/41) at 4 years. There were no differences in the rate of HBV DNA disappearance from serum between the patients with and without HCC: 57% (8/14) vs. 54% (105/193) at 1 year (*P* = 1.0); 86% (12/14) vs. 70% (107/154) at 2 years (*P* = 0.229); and 89% (8/9) vs.

Table 1 Characteristics of patients who did and did not develop hepatocellular carcinoma (HCC) at the start of adefovir

	HCC developed (n = 18)	HCC did not develop (n = 129)	Differences P-value
Duration of lamivudine before the start of adefovir	128 (31–346)	144 (13–617)	0.321
Age (years)	52 (35–75)	45 (26–75)	0.008
Men	15 (83%)	183 (80%)	1.000
Cirrhosis	10 (56%)	51 (22%)	0.004
Platelets ($\times 10^3/\text{mm}^3$)	12.0 (4.6–19.7)	16.3 (3.1–31.9)	0.001
Albumin (g/dL)	3.6 (2.3–4.7)	3.9 (2.8–4.7)	0.073
Bilirubin (mg/dL)	0.8 (0.5–15.5)	0.7 (0.2–6.0)	0.046
Creatinine (mg/dL)	0.8 (0.5–1.0)	0.8 (0.4–1.6)	0.950
AST (IU/L)	119 (55–248)	66 (14–1413)	0.003
ALT (IU/L)	151 (61–576)	104 (13–1563)	0.035
AFP (ng/dL)	8 (2–130)	4 (1–282)	0.026
HBV genotypes			0.228
C	18 (100%)	189 (87%)	
Others	0	27 (13%)	
HBeAg	8 (44%)	132 (58%)	0.373
HBV DNA (log copies/mL)	7.1 (4.4–7.6)	7.1 (<2.6–>7.6)	0.623
YMDD mutants			0.041
YIDD	13 (72%)	109 (45%)	
YVDD	5 (28%)	62 (25%)	
YI/VDD	0	56 (23%)	

†Values are the median with the range in parentheses or *n* with percent in parentheses.

AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.

92% (85/92) at 3 years ($P = 0.555$). Rates of normalized AST levels in the patients with and without HCC were: 50% (7/14) vs. 90% (173/193) at 1 year ($P < 0.001$); 79% (11/14) vs. 91% (140/154) at 2 year ($P = 0.166$); and 67% (6/9) vs. 95% (87/92) at 3 year ($P = 0.037$). Rates of ALT normalization in the patients with and without HCC were: 71% (10/14) vs. 90% (174/193) at 1 year ($P = 0.037$); 79% (11/14) vs. 90% (139/154) at 2 year ($P = 0.189$); and 56% (5/9) vs. 92% (85/92) at 3 year ($P = 0.015$). Thus, normalization of AST and ALT was less frequent in the patients with than without HCC.

Characteristics of the 18 patients who developed HCC are compared between the baseline and at the development of HCC (Table 2). At the start of adefovir, 10 (56%) of them had developed cirrhosis and 16 (89%) had AST levels ≥ 70 IU/L. HBV DNA was not detectable in 10 (56%) of them at the development of HCC. Of the eight patients with detectable HBV DNA levels (≥ 2.6 log copies/mL), five (63%) developed HCC within 1 year after the start of adefovir. AST was elevated (≥ 38 IU/L) in eight patients, including four (50%) without detectable HBV DNA levels.

Factors independently associated with the development of hepatocellular carcinoma

Eight factors associated with the development of HCC by the univariate analysis, including age, cirrhosis, platelet counts, bilirubin, AST, ALT and AFP levels, as well as YMDD mutants (Table 1), were evaluated by the multivariate analysis. AST ≥ 70 IU/L, YIDD mutants, age ≥ 50 years and cirrhosis at the baseline were independent risk factors for the development of HCC (Table 3). There were no differences in the distribution of YIDD, YVDD and the mixture thereof among the patients with distinct AST, ALT or HBV DNA levels or between those with and without cirrhosis at the start of adefovir. HBV mutants with mutations resistant to adefovir (rtA181T/S, rtN236T) occurred in two of the 247 (0.8%) patients; none of them developed HCC.

The median time between the elevation of HBV DNA ≥ 5.0 log copies/mL and the administration of adefovir was 124 (range: 0–815) days for the 13 patients who developed HCC and 147 (0–3268) days for the 166 patients who did not ($P = 0.605$). The median time between the elevation of ALT ≥ 43 IU/L and the start of

Table 2 Characteristics of the 18 patients at commencement of adefovir (ADV) and development of hepatocellular carcinoma (HCC)

Patient no.	Age (years)	Sex	At the commencement of ADV					Period of ADV (years)		At the development of HCC		
			Liver disease	AST (IU/L)	ALT (IU/L)	HBeAg	HBV DNA (log copies/mL)	YVDD mutant	ADV	AST (IU/L)	ALT (IU/L)	HBV DNA (log copies/mL)
1	50	M	CH	248	576	-	6.9	I	4.5	26	27	<2.6
2	35	M	LC	217	164	+	7.5	I	1.6	54	34	<2.6
3	50	M	LC	192	272	+	>7.6	I	1.2	68	89	<2.6
4	61	M	CH	192	332	-	6.9	I	2.8	22	23	<2.6
5	65	M	CH	174	219	-	5.2	V	0.1	30	43	<2.6
6	58	M	CH	160	216	-	6.5	V	2.2	41	32	<2.6
7	53	M	LC	127	97	+	>7.6	I	0.5	55	41	3.2
8	75	M	LC	119	209	+	>7.6	V	1.1	121	125	2.6
9	58	F	CH	118	214	+	4.4	I	3.3	21	13	<2.6
10	48	M	CH	116	99	+	>7.6	I	3.3	32	36	<2.6
11	51	F	LC	111	130	-	5.3	I	0.9	88	95	<2.6
12	47	M	CH	85	138	+	>7.6	I	1.3	28	29	3.1
13	61	M	LC	81	65	-	5.6	I	0.2	32	27	2.9
14	59	F	LC	80	132	-	>7.6	V	0.1	32	41	3.2
15	40	M	LC	75	124	-	6.3	I	3.8	21	24	<2.6
16	48	M	CH	71	61	-	6.6	I	0.6	48	26	3.7
17	55	M	LC	55	76	+	7.3	I	0.2	50	64	5.4
18	43	M	LC	27	21	-	5.4	V	1.6	30	23	3.7

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CH, chronic hepatitis; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; I, YIDD mutant; LC, cirrhosis; V, YVDD mutant.

Table 3 Independent risk factors influencing the development of hepatocellular carcinoma

Factors	Category	Hazard ratio (95% CI)†	P-value
AST (IU/l)	1: < 70	1	0.016
	2: ≥ 70	6.21 (1.40-27.5)	
YMDD mutants	1: YVDD or YV/IDD	1	0.012
	2: YIDD	3.97 (1.36-11.6)	
Age (years)	1: < 50	1	0.023
	2: ≥ 50	3.24 (1.17-8.95)	
Cirrhosis	1: Absent	1	0.030
	2: Present	1.42 (1.04-1.96)	

†Confidence interval.

adefovir was 59 (0-896) days for the patients who developed HCC and 54 (0-3240) days for those who did not ($P = 0.330$). Hence, exacerbation of hepatitis was not a risk factor for the development of HCC.

Age-specific risk factors for the development of HCC were evaluated by the multivariate analysis. In the patients < 50 years, platelet counts $< 13 \times 10^3/\text{mm}^3$ was the only significant risk factor for HCC (hazard ratio 6.88 [95% confidence interval; 1.26-37.6]), while AST levels ≥ 70 IU/L was that in those ≥ 50 years (hazard ratio: 9.50 [95% confidence interval 1.20-74.9]).

Factors increasing the cumulative incidence of hepatocellular carcinoma

AST levels ≥ 70 IU/L at the start of adefovir increased the development of HCC during follow-ups ranging to 5 years (Fig. 1). HCC developed more frequently in the patients with YIDD mutants than in those with YVDD or the mixture of YVDD and YIDD mutants (Fig. 2). The cumulative incidence of HCC in the patients with YIDD mutants alone was: 4% at 1 year, 10% at 3 years and 43% at 5 years. In contrast, HCC never developed in the patients with the mixture of YIDD and YVDD mutants through 5 years of follow-up. HCC developed more frequently in the patients with cirrhosis and those aged ≥ 50 years (Figs 3,4, respectively).

DISCUSSION

HCC DEVELOPED IN 18 of the 247 (7.3%) patients who had received adefovir add-on lamivudine during a long-term ranging to 5 years. There were some differences in the characteristics at the start of adefovir dipivoxil between the patients who did and who did not




Figure 1 Kaplan-Meier life-table for the cumulative incidence of hepatocellular carcinoma (HCC) during adefovir add-on lamivudine in the patients with different baseline aspartate aminotransferase (AST) levels. * $P = 0.009$.

develop HCC. The patients who developed HCC were older, more frequently had signs of early cirrhosis with less platelet counts, as well as higher levels of AST, ALT and AFP, than those who did not develop HCC. By multivariate analysis, AST ≥ 70 IU/L, YIDD mutants in




Figure 2 Kaplan-Meier life-table for the cumulative incidence of hepatocellular carcinoma (HCC) during adefovir add-on lamivudine in the patients with distinct YMDD mutants. * $P = 0.035$; † $P = 0.003$.




Figure 3 Kaplan-Meier life-table for the cumulative incidence of hepatocellular carcinoma (HCC) during adefovir add-on lamivudine in the patients with and without cirrhosis at the baseline. * $P = 0.002$.

comparison with YVDD or the mixture of YVDD and YIDD mutants, age ≥ 50 years and cirrhosis were independent risk factors for the development of HCC. By the Kaplan-Meier life-table analysis, the cumulative incidence of HCC during 5 years in the patients receiving




Figure 4 Kaplan-Meier life-table for the cumulative incidence of hepatocellular carcinoma (HCC) during adefovir add-on lamivudine in the patients aged ≥ 50 years and < 50 years at the baseline. $P = 0.014$.

adefovir add-on lamivudine was significantly higher in those with AST ≥ 70 IU/L, YIDD mutants, cirrhosis and aged ≥ 50 years at the start of adefovir.

A marked difference in the development of HCC between the present study (7.3% [18/247]) and two studies reported from Europe and the US (0/70 and 0/65, respectively)^{16,17} would be accounted for, at least in part, by the age of patients who developed HCC in this study that was older than in those in previous reports (the median of 52 years vs. means of 36 and 47 years, respectively). This view would be supported by the age of patients with long-term adefovir add-on lamivudine that was higher in those with than without the development of HCC (52 vs. 45 years [median], $P = 0.008$). HBV infection in Asia is acquired by the perinatal infection, while that in Western countries is gained after the adolescence ~ 20 years after birth. Hence, the duration of HBV infection would have been > 20 years longer in Japanese than Western patients. In addition, genotypes of HBV may give an additional account on the difference in development of HCC between them. All the 18 patients who developed HCC in this study were infected with genotype C; it is associated with HCC more closely than the other genotypes.²⁰⁻²³ By contrast, by far the most patients from Western countries would have been infected with genotypes A and D.^{24,25}

HCC developed more frequently in patients with than without cirrhosis at the start of adefovir (10/61 [16.4%] vs. 8/186 [4.3%], $P = 0.002$). Hence, cirrhosis increased the risk of HCC in patients receiving adefovir add-on lamivudine. This view is supported by the development of HCC in 11 of the 94 (11.7%) patients with cirrhosis who received adefovir add-on lamivudine from Italy.¹⁰ Although HCC did not develop in any of the 39 Italian patients with chronic hepatitis, it did in eight of the 186 (4.3%) Japanese patients in the present study. There were, however, marked differences in the median baseline ALT levels between Italian and Japanese patients (58 vs. 108 IU/L); the grade of liver inflammation would have been higher in the Japanese patients. In actuality, all the eight patients with chronic hepatitis who developed HCC had high AST and ALT levels at the start of adefovir (Table 2).

In the natural history of persistent HBV infection, HCC develops more frequently in the patients with persistently high ALT levels than in those with normal levels. Hence, necroinflammation in the liver would contribute to carcinogenesis.^{26,27} Although adefovir add-on lamivudine may prevent virological breakthroughs, it would not be able to suppress the pre-

neoplastic state induced by exacerbation of hepatitis. It would be necessary therefore to identify the patients with chronic hepatitis at an increased risk for HCC during adefovir add-on lamivudine, such as those with cirrhosis or aged ≥ 50 years, and take special care of them toward early detection of HCC and immediate therapeutic intervention. They need to be monitored frequently for any increase in HBV DNA and aminotransferase levels that herald breakthrough hepatitis during lamivudine therapy.

In the present study, HCC developed more frequently in the patients with YIDD mutants than in those with YVDD or the mixture of YVDD and YIDD; there have been no studies correlating YMDD mutants and the development of HCC. No patients with the mixture of YVDD and YIDD mutants developed HCC, despite the predominance of YIDD mutants in the patients with HCC. This might have been due to the assay used for YMDD mutants by the commercial kit; it can miss YVDD mutants in samples in which YIDD mutants account for the great majority. By the assay method specific for either mutant, YIDD was detected either alone or accompanied by small amount of YVDD in the patients who have received adefovir add on lamivudine treatment.³⁵ Sensitive and specific quantification of YIDD and YVDD mutants are necessary for further evaluating a role for YIDD mutants in hepatocarcinogenesis, as well as for identifying factors promoting the generation of both YIDD mutants and HCC.

Some points of clinical importance have emerged in the present study. First, patients who receive a long-term adefovir add-on lamivudine and have developed YMDD mutants need to be screened for HCC on the regular basis. This is required especially for the patients who have signs of cirrhosis and/or high AST levels, or aged ≥ 50 years. In these high-risk patients, adefovir has to be started promptly when HBV DNA levels increase, even before transaminase levels elevate in them. Secondly, it would be a matter of concern if adefovir is involved in the development of HCC. Should it be the case, tenofovir or newer potent antivirals, either as a monotherapy or add on lamivudine, would deserve considerations. Thirdly, it needs to be evaluated if YIDD mutants have any significance in the development of HCC. Although nucleot(s)ide analogues may suppress hepatic inflammation and are expected to improve the prognosis of patients with chronic hepatitis B, they need to be monitored closely for HCC. The development of HCC has to be identified, as early as possible, for timely treatment toward longevity with minimal morbidity and improvement of the quality of life.

ACKNOWLEDGEMENTS

THIS WORK WAS sponsored in part by grants from the Ministry of Health, Labour and Welfare of Japan.

REFERENCES

- 1 Lee WM. Hepatitis b virus infection. *N Engl J Med* 1997; 337: 1733-45.
- 2 Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. *N Engl J Med* 2004; 350: 1118-29.
- 3 Dienstag JL. Hepatitis B virus infection. *N Engl J Med* 2008; 359: 1486-500.
- 4 Jarvis B, Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. *Drugs* 1999; 58: 101-41.
- 5 Dando T, Plosker G. Adefovir dipivoxil: a review of its use in chronic hepatitis B. *Drugs* 2003; 63: 2215-34.
- 6 Akuta N, Suzuki F, Kobayashi M *et al*. Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy. *J Med Virol* 2003; 71: 504-10.
- 7 Suzuki F, Suzuki Y, Tsubota A *et al*. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. *J Hepatol* 2002; 37: 324-30.
- 8 Keeffe EB, Dieterich DT, Han SH *et al*. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. *Clin Gastroenterol Hepatol* 2006; 4: 936-62.
- 9 Lok AS, McMahon BJ. Chronic hepatitis B. *Hepatology* 2007; 45: 507-39.
- 10 Lampertico P, Vigano M, Manenti E, Lavarone M, Salloum E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine resistant hepatitis B patients. *Gastroenterology* 2007; 133: 1445-51.
- 11 Yasunji H, Suzuki F, Sezaki H *et al*. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. *J Hepatol* 2008; 48: 923-31.
- 12 Fumada H. Continued lamivudine therapy in patients with chronic hepatitis B. *Intervirology* 2003; 46: 377-87.
- 13 Hosaka T, Suzuki F, Suzuki Y *et al*. Factors associated with the virological response of lamivudine resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. *J Gastroenterol* 2007; 42: 368-74.
- 14 Hosaka T, Suzuki F, Suzuki Y *et al*. Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus. *Intervirology* 2004; 47: 362-9.
- 15 Delaney WE IV. Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. *J Antimicrob Chemother* 2007; 59: 327-32.

- 16 Hadziyannis SJ, Tassopoulos NC, Heathcote EJ *et al.* Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. *Gastroenterology* 2006; 131: 1743–51.
- 17 Marcellin P, Chang TT, Lim SG *et al.* Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. *Hepatology* 2008; 48: 750–8.
- 18 Usuda S, Okamoto H, Iwanari H *et al.* Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. *J Virol Methods* 1999; 80: 97–112.
- 19 Usuda S, Okamoto H, Tanaka T *et al.* Differentiation of hepatitis B virus genotypes D and E by ELISA using monoclonal antibodies to epitopes on the preS2-region product. *J Virol Methods* 2000; 87: 81–9.
- 20 Livingston SE, Simonetti JP, Bulkow LR *et al.* Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. *Gastroenterology* 2007; 133: 1452–7.
- 21 Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. *Gastroenterology* 2000; 118: 554–9.
- 22 Orito E, Ichida T, Sakugawa H *et al.* Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. *Hepatology* 2001; 34: 590–4.
- 23 Tsubota A, Arase Y, Ren F, Tanaka H, Ikeda K, Kumada H. Genotype may correlate with liver carcinogenesis and tumor characteristics in cirrhotic patients infected with hepatitis B virus subtype adw. *J Med Virol* 2001; 65: 257–65.
- 24 Chu CJ, Keeffe EB, Han SH *et al.* Hepatitis B virus genotypes in the United States: results of a nationwide study. *Gastroenterology* 2003; 125: 444–51.
- 25 Miyakawa Y, Mizokami M. Classifying hepatitis B virus genotypes. *Intervirology* 2003; 46: 329–38.
- 26 Chen CJ, Yang HI, Su J *et al.* Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA* 2006; 295: 65–73.
- 27 Wu CF, Yu MW, Lin CL *et al.* Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. *Carcinogenesis* 2008; 29: 106–12.
- 28 Suzuki F, Kumada H, Nakamura H. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy. *J Med Virol* 2006; 78: 1025–34.

Review Article

Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan

Hiromitsu Kumada,¹ Takeshi Okanoue,² Morikazu Onji,³ Hisataka Moriwaki,⁴ Namiki Izumi,⁵ Eiji Tanaka,⁶ Kazuaki Chayama,⁷ Shotaro Sakisaka,⁸ Tetsuo Takehara,⁹ Makoto Oketani,¹⁰ Fumitaka Suzuki,¹¹ Joji Toyota,¹² Hideyuki Nomura,¹³ Kentaro Yoshioka,¹⁴ Masataka Seike,¹⁵ Hiroshi Yotsuyanagi,¹⁶ Yoshiyuki Ueno¹⁷ and The Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis, Ministry of Health, Labor and Welfare of Japan

¹Department of Hepatology, Toranomon Hospital, Tokyo, ²Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Suita, ³Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, ⁴Department of Internal Medicine, Gifu University, Gifu, ⁵Department of Gastroenterology and Hepatology, Musashino Red-Cross Hospital, Musashino, ⁶Department of Internal Medicine, Shinshu University, Matsumoto, ⁷Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, Hiroshima, ⁸Department of Gastroenterology and Hepatology, Fukuoka University School of Medicine, Fukuoka, ⁹Department of Gastroenterology and Hepatology, Osaka University, Osaka, ¹⁰Department of Digestive and Lifestyle-related Disease, Health Research Human and Environmental Science, Kagoshima, ¹¹Department of Hepatology, Toranomon Hospital, Tokyo, ¹²Department of Gastroenterology, Sapporo Kosei General Hospital, Sapporo, ¹³The Center of Liver Disease, Shin-Kokura Hospital, Kitakyusyu City, ¹⁴Division of Liver, Biliary Tract and Pancreas Disease, Department of Internal Medicine, Fujita Health University, Aichi, ¹⁵Department of Internal Medicine, Faculty of Medicine, Oita University, Oita, ¹⁶Department of Infectious Disease, University of Tokyo, Tokyo, and ¹⁷Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan

In the 2008 guidelines for the treatment of patients with cirrhosis, who are infected with hepatitis B virus (HBV), the main goal is to normalize levels of alanine and aspartate aminotransferases by eliminating HBV or reducing viral loads. In patients with compensated cirrhosis, the clearance of HBV from serum is aimed for by entecavir, as the main resort, for histological improvement toward the prevention of hepatocellular carcinoma (HCC). In patients with decompensated cirrhosis, by contrast, meticulous therapeutic strategies are adopted for the reversal to compensation, toward the eventual goal of decreasing the risk of HCC. For maintaining liver function and preventing HCC, branched chain amino acids and nutrient supplements are applied, in addition to conventional liver supportive therapies. For patients with chronic hepatitis B, separate guidelines are applied to those younger than 35 years and those aged 35 years or older. Even for patients

with chronic hepatitis who are negative for hepatitis e antigen (HBeAg), but who harbor HBV DNA in titers of 7 log copies/mL or more, a “drug-free state” is aimed for by sequential treatment with interferon (IFN) plus entecavir as the first line. For patients with chronic hepatitis B aged 35 years or older, who are HBeAg-negative and carry HBV DNA in titers of less than 7 log copies/mL, long-term IFN for 24–48 weeks is adopted anew. To HBeAg-negative patients who have either or both platelet counts of less than $150 \times 10^9/\text{mm}^3$ and less than 7 log copies of HBV DNA, also, long-term IFN for 24–48 weeks is indicated.

Key words: chronic hepatitis, cirrhosis, hepatitis B virus, hepatocellular carcinoma, interferon, liver supportive therapies, nucleos(t)ide analogs

Correspondence: Dr Hiromitsu Kumada, Department of Hepatology, Toranomon Hospital, 1-3-1 Kajigaya, Takatsu-ku, Kawasaki City 213-8587, Japan. Email: kumahi@toranomon.gr.jp

Received 26 October 2009; revision 4 November 2009; accepted 11 November 2009.

INTRODUCTION

SINCE THE FISCAL year 2002, guidelines for the treatment of patients with viral hepatitis have been compiled annually by the Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis, under the auspice of the Ministry of Health, Labor and Welfare of Japan, supported by enduring efforts of many specialists recruited from all over the nation. Guidelines have been improved every year with many supplementary issues, which had surfaced as our understanding of many facets of viral hepatitis deepened and treatment options widened increasingly with time. For the fiscal year 2008, guidelines have been worked out for a comprehensive standardization of the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in Japan. These guidelines have been observed by more than 70% of practicing hepatologists treating patients with viral liver disease in Japan. It is hoped that these guidelines will continue being widely accepted and implemented to help as many patients as possible who are suffering from sequelae of persistent hepatitis virus infections.

Here, we relate excerpts of the 2008 guidelines for the treatment of patients with liver disease due to HBV, covering a wide range from those with chronic hepatitis to those with decompensated cirrhosis. The 2008 guidelines for the treatment of liver disease due to HCV are reported in an accompanying paper.

GUIDELINES FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B

PATIENTS WITH CHRONIC hepatitis B can stabilize the activity of liver disease in their natural course, after they have seroconverted from hepatitis B e antigen (HBeAg) to the corresponding antibody (anti-HBe), accompanied by decrease in HBV DNA titers. For that reason, treatment guidelines were constructed separately for the patients younger than 35 years and those aged 35 years or older.

GUIDELINES FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B YOUNGER THAN 35 YEARS

PATIENTS WITH CHRONIC hepatitis B younger than 35 years are treated in accordance with the guidelines summarized in Table 1. Criteria for the treatment eligibility are: (i) serum levels of alanine aminotransferase (ALT) of 31 IU/L or more; and (ii) HBV DNA titers of 5 log copies of more in HBeAg-positive patients and 4 log copies or more in HBeAg-negative patients. In the 2008 guidelines, the indication of treatment is extended to the patients with cirrhosis due to HBV who carry HBV DNA in titers of 3 log copies/mL or more.

In Japan, most HBeAg-positive patients with 7 log copies or more of HBV DNA have been infected with HBV of genotype C by perinatal infection at birth;

Table 1 Guidelines for the treatment of patients with chronic hepatitis B younger than 35 years

Eligibility criteria	ALT HBV DNA	≥31 IU/L HBeAg-positive patients: ≥5 log copies/mL HBeAg-negative patients: ≥4 log copies/mL Patients with cirrhosis: ≥3 log copies/mL
HBV DNA	≥7 log copies/mL	<7 log copies/mL
HBeAg-positive	(1) Long-term IFN for 24–48 weeks (2) Entecavir	(1) Long-term IFN for 24–48 weeks (2) Entecavir
HBeAg-negative	(1) Sequential treatment† (entecavir plus IFN) (2) Entecavir Start with entecavir in HBeAg-negative patients who have platelet counts <15 × 10 ³ /mm ³ and in those with advanced liver disease of stage F2 or higher.	(1) Regular follow up (2) Long-term IFN for 24 weeks

†Sequential treatment: patients who have lost hepatitis B virus (HBV) DNA after treatment with nucleos(t)ide analogs receive combined interferon (IFN) for 4 weeks, and then IFN monotherapy is continued for 20 weeks, and lifted thereafter. ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen.

Table 2 Guidelines for the treatment of patients with chronic hepatitis B aged 35 years or older

Eligibility criteria	ALT HBV DNA	≥31 IU/L HBeAg-positive patients: ≥5 log copies/mL HBeAg-negative patients: ≥4 log copies/mL Patients with cirrhosis: ≥3 log copies/mL
HBV DNA	≥7 log copies/mL	<7 log copies/mL
HBeAg-positive	(1) Entecavir (2) Sequential treatment† (entecavir plus IFN)	(1) Entecavir (2) Long-term IFN for 24–48 weeks
HBeAg-negative	Entecavir	(1) Entecavir (2) Long-term IFN for 24–48 weeks

†Sequential treatment: patients who have lost hepatitis B virus (HBV) DNA after treatment with nucleos(t)ide analog receive combined interferon (IFN) for 4 weeks, and then IFN monotherapy is continued for 20 weeks, and lifted thereafter. ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen.

accordingly, they would be resistant to interferon (IFN) therapy. Should they receive nucleos(t)ide analogs, however, the duration would become inevitably longer, because they start the treatment when younger than 35 years old. Hence, IFN for 24–48 weeks is the first choice in their treatment. The standard treatment of 3 months is favored, which can be extended to the maximum of 6 months. Non-pegylated (standard) IFN- α is recommended to them, because self-injection at home is approved for preparations of IFN- α ; it helps improve their quality of life (QOL). There are many patients who are refractory to IFN and in whom improvement of ALT levels and/or decrease in HBV DNA titers are hardly achievable. Therefore, as another option, monotherapy with entecavir can be applied for the purpose of clearing HBeAg from serum and lowering HBV DNA titers. For HBeAg-positive patients with lower HBV DNA titers (<7 log copies/mL), also, long-term IFN is endorsed as a rule.

There are HBeAg-negative patients in whom ALT levels increase to 31 IU/mL or more repeatedly. In the 2008 guidelines, sequential treatment with IFN and entecavir is introduced as a new arm of therapeutic options for such patients.¹

For HBeAg-negative patients with less than 7 copies/mL of HBV DNA, in general, regular follow up without therapeutic intervention is deemed to suffice for the majority. For those of them in whom ALT levels flare to 31 IU/mL or more time after time, long-term IFN for 24 weeks is indicated. Because liver disease progresses in many HBeAg-negative patients, for those with platelet counts of less than $150 \times 10^3/\text{mm}^3$ or in fibrosis stage F2 or higher, treatment with entecavir is indicated.

GUIDELINES FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B AGED 35 YEARS OR OLDER

TABLE 2 SUMS up treatment modalities for patients with chronic hepatitis B who are aged 35 years or older. HBeAg-positive patients in this age range who carry HBV DNA in titers of 7 log copies/mL or more rarely, if ever, seroconvert to the loss of HBeAg by IFN-based therapies. Hence, entecavir is the first choice in their treatment.^{2,3} Because HBV mutants resistant to entecavir can be elicited by it, sequential treatment with IFN plus entecavir is amended in the 2008 guidelines.¹ In view of low viral loads in patients who possess HBV DNA in titers of less than 7 log copies/mL, entecavir is selected as the first choice, followed by long-term IFN as the second choice of treatment in these patients. HBeAg-negative patients who have high viral loads (≥7 log copies/mL), on the other hand, can normalize ALT levels by monotherapy with entecavir. Therefore, entecavir becomes their first choice, and this is the case even in patients with HBV DNA titers less than 7 copies/mL.

GUIDELINES FOR THE TREATMENT WITH NUCLEOS(T)IDE ANALOGS OF PATIENTS WITH CHRONIC HEPATITIS B WHO ARE RECEIVING LAMIVUDINE

TABLE 3 DETAILS guidelines for the treatment with nucleos(t)ide analogs of patients with chronic hepatitis B who are receiving lamivudine. Because a number of drug-resistant HBV mutants emerge increasingly with time in patients on long-term treatment with lamivudine, the fundamental rule is to switch them to ente-

Table 3 Guidelines for the treatment with nucleos(t)ide analogs in patients with chronic hepatitis who are receiving lamivudine

Lamivudine	Less than 3 years	3 years or longer
HBV DNA		
<1.8 log copies/mL persistently	May be switched to entecavir 0.5 mg daily	Continued on lamivudine
≥1.8 log copies/mL	VBT (-) May be switched to entecavir 0.5 mg daily VBT (+) Adefovir 10 mg daily add-on lamivudine	100 mg daily Adefovir 10 mg daily add-on lamivudine

HBV, hepatitis B virus; VBT, virological breakthrough.

cavir. For this reason, patients are stratified by the duration of lamivudine treatment, less than 3 years and 3 years or more, as well as HBV DNA titers persistently below 1.8 log copies/mL and 1.8 log copies/mL or more, and separate treatment strategies have been worked out for the patients in each category. Because by far the majority of patients with a duration of lamivudine treatment of less than 3 years and HBV DNA titers of less than 1.8 copies/mL possess drug-resistant mutants in low frequencies, they are recommended to switch to entecavir 0.5 mg daily as soon as possible. Likewise, patients who have received lamivudine for 3 years or longer, but in whom drug-resistant mutants have never developed, are recommended to switch to entecavir 0.5 mg daily. By contrast, for patients in whom drug-resistant mutants have emerged already and who have undergone virological breakthroughs,⁴ adefovir 10 mg daily add-on lamivudine is started for the purpose of stabilizing liver function.⁵ In regard of the patients who have received lamivudine for 3 years or longer, those without drug-resistant mutants can stay on lamivudine 100 mg daily.

SUPPLEMENTS TO GUIDELINES FOR THE TREATMENT OF CHRONIC HEPATITIS B (PART I)

FOR THE FISCAL year 2008, the following three items have been added to previous guidelines for the treatment of chronic hepatitis B (Table 4).

1 In the treatment of patients with chronic hepatitis B, IFN is the first resort for those younger than 35 years, toward the eventual goal of gaining a “drug-free state”. For the patients aged 35 years or older, persistently negative HBV DNA is the aim of nucleos(t)ide analogs, with the first choice being entecavir in their primary treatment. On the other hand, for patients with HBV mutants resistant to lamivudine and/or entecavir, combined treatment with adefovir and lamivudine is the principal rule (Table 3).^{6–8}

- 2 Therapeutic responses to antiviral treatment are much different in patients with chronic hepatitis B who are infected with HBV of distinct genotypes. It is recommended therefore to determine HBV genotypes before making a decision on the treatment choice. In particular, the patients infected with HBV of genotype A or B respond to IFN in high rates, even if they are aged 35 years or older. For these reasons, IFN becomes the first choice in their antiviral treatment.
- 3 The duration of IFN treatment is 24 weeks basically. In the patients in whom the efficacy of IFN has been achieved with decrease in HBV DNA titers and normalization of ALT, the treatment duration is better extended to 48 weeks.

Table 4 Supplements to guidelines for the treatment of patients with chronic hepatitis B (part I)

- 1 Treatment of patients with chronic hepatitis B aims at a “drug-free state” by IFN-based therapies in those younger than 35 years, and at persistently negative HBV DNA in those aged 35 years or older, with entecavir as the first choice in the primary therapy. Lamivudine plus adefovir forms the basis for the treatment of HBV mutants resistant to lamivudine or entecavir.
- 2 In view of antiviral response much different in patients infected with HBV of distinct genotypes, it is desired to make treatment choices based on genotypes. In particular, because genotypes A and B respond to IFN with high efficacy, even in patients aged 35 years or older, IFN is recommended as the first treatment choice in these patients.
- 3 The duration of IFN is for 24 weeks basically, but extension to 48 weeks is recommended in patients who respond to IFN with decrease in HBV DNA titers and normalization of ALT levels.

ALT, alanine aminotransferase; HBV, hepatitis B virus; IFN, interferon.